United-Guardian 3Q 2026: Revenue $3.49M, EPS $0.2 — 10-Q Summary
United-Guardian reported 3Q 2026 revenue of $3.49M, up 54% YoY, with EPS of $0.2. Growth was driven by pharmaceuticals, cosmetic ingredients, and medical lubricants. Pharmaceutical sales rose 29% due to Renacidin formulary coverage, while cosmetic ingredient sales climbed 187% after ASI resumed purchases. Medical lubricant sales increased 20%, and cost of sales fell to 46% of revenue.
How this was made
The 30-second read
Why it matters
The earnings beat and revenue surge could trigger a short‑term rally, especially in after‑hours trading.
Market read
Earnings surprise for a micro‑cap biotech/chemicals firm; relevance mainly to sector‑focused traders.
What to watch
The report does not disclose guidance; future performance depends on continued demand from ASI and Indian client.
Background
United-Guardian filed its Form 10‑Q for Q3 2026, providing the first public earnings numbers for the period.
Ticker impact
United-Guardian reported Q3 2026 revenue of $3.49M, up 54% YoY, and EPS $0.20, marking the first public disclosure of these results.
upward pressure as investors price in higher revenue and earnings growth
Revenue and EPS both rose sharply year‑over‑year, indicating improved demand across pharmaceuticals, cosmetics, and medical lubricants.
Market effects
Boosts outlook for specialty pharma and cosmetic ingredient suppliers.
May benefit peers with exposure to Indian medical lubricant market.
Limited to niche specialty chemicals sector.
Counterpoint
Growth may be unsustainable if key customers reduce orders after inventory normalization.
Key entities
- companyUnited-Guardian Inc.
Specialty chemicals and pharmaceutical ingredients producer.